Human Papilloma Virus 16 E2 (HPV-16 E2) antibody
Quick Overview for Human Papilloma Virus 16 E2 (HPV-16 E2) antibody (ABIN6937435)
Target
Reactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purification
- Purified by Protein A/G
-
Immunogen
- Raised against Vaccinia-E2 followed by intravenous injection of the maltose binding protein MBP-E2
-
Isotype
- IgG1 kappa
-
-
-
-
Application Notes
-
Positive Control: HPV-16 infected cells. Cervical tissue.
Known Application: Western Blot (1-2 μg/mL), Optimal dilution for a specific application should be determined.
-
Restrictions
- For Research Use only
-
-
-
Buffer
- 10 mM PBS without BSA and without Azide.
-
Preservative
- Azide free
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months.
-
Expiry Date
- 24 months
-
-
- Human Papilloma Virus 16 E2 (HPV-16 E2)
-
Alternative Name
- HPV16 E2 (Human Papilloma Virus 16)
-
Target Type
- Viral Protein
-
Background
- The human papilloma virus (HPV) family of DNA tumor viruses includes HPV16, a strain that is responsible for the largest number of cases of cervical cancers linked to the family. HPV16E1 and HPV16E2 are proteins that are involved in the regulation of viral DNA replication and are important for infected cell homeostasis. HPV16E2 specifically regulates the expression of the E6 and E7 oncoproteins by binding to four sites within the viral long control region, possibly involving interactions with nuclear hormone receptors. Integration of the HPV genome into the host DNA usually disrupts the HPV16E2 gene open reading frames, resulting in an overexpression of E6 and E7 genes, an event that may lead to the malignant transformation of cervical cancer. HPV16E2 is also able to induce apoptotic cell death via two pathways: the first through the binding of p53 and the second through the binding of the viral genome.
-
Molecular Weight
- 43kDa
Target
-